文献速递急性肾损伤

儿童患者对比剂后急性肾损伤:一项队列研究

Postcontrast Acute Kidney Injury in Pediatric Patients: A Cohort Study.
PubMed 文献 · Am J Kidney Dis · 2018-07-21

倾向性评分分析显示,对比剂组与非对比剂组在急性肾损伤、透析治疗或死亡风险上无显著差异。对比剂后急性肾损伤、透析和死亡率均很低,但不能排除对比剂对这些结局的影响。

要点

  • 儿童增强CT后急性肾损伤发生率3.3%,透析治疗率0.1%。
  • 倾向性评分调整后,对比剂组与非对比剂组急性肾损伤、透析或死亡风险无显著差异。
  • 所有对比剂后3期急性肾损伤患者均有非对比剂相关的潜在病因。

核心结论

  • 儿童增强CT后急性肾损伤、透析治疗和死亡率很低,但对比剂对这些结局的影响不能排除。

主要发现

  • 对比剂组急性肾损伤发生率3.3%(59/1773),透析治疗率0.1%(2/1773)。
  • 倾向性评分调整后,1期急性肾损伤OR 0.75(95%CI 0.32-1.78,P=0.5),2期OR 2.00(95%CI 0.18-21.9,P=0.6),3期OR 0.50(95%CI 0.05-5.48,P=0.6)。
  • 透析治疗OR 1.00(95%CI 0.06-15.9,P=0.9),死亡OR 1.50(95%CI 0.53-4.22,P=0.4)。
  • 所有对比剂后3期急性肾损伤患者均有非对比剂相关的潜在病因。

关键数值与推荐

  • 急性肾损伤依据血肌酐定义的KDIGO标准。

临床怎么用

  • 儿童增强CT后急性肾损伤和透析风险很低,但需注意对比剂后3期急性肾损伤患者常存在其他病因。

局限性

  • 样本量小且对比剂后急性肾损伤、透析和死亡发生率低,限制了检测对比剂效应的能力。
  • 未测量的残余混杂因素可能影响结果有效性。
  • 少数患者在CT时肾功能已下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONAL & OBJECTIVE: The risks of iodinated contrast material administered to pediatric patients are not well defined. The purpose of this study was to examine the rates of postcontrast acute kidney injury (AKI), dialysis therapy, and death following administration of intravenous contrast material to pediatric patients. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Pediatric (aged <18 years) patients who underwent either contrast-enhanced (contrast group) or unenhanced (noncontrast group) computed tomography (CT) at our institution from December 2001 to January 2016. EXPOSURE: Intravenous iodinated contrast material. OUTCOMES: Postcontrast AKI based on serum creatinine-defined KDIGO criteria, dialysis therapy, and death. ANALYTICAL APPROACH: Risks for AKI, dialysis therapy, and death were compared between contrast and noncontrast group patients using a propensity score analysis incorporating clinical covariates related to contrast exposure. RESULTS: 2,201 pediatric patients (1,773 contrast and 428 noncontrast) were identified. Rates of AKI and dialysis therapy in the contrast group were 3.3% (59/1,773) and 0.1% (2/1,773), respectively. Following propensity score adjustment, no differences in risk for AKI (stage 1 AKI: OR, 0.75 [95% CI, 0.32-1.78], P=0.5; stage 2: OR, 2.00 [95% CI, 0.18-21.9], P=0.6; stage 3: OR, 0.50 [95% CI, 0.05-5.48], P=0.6), dialysis therapy (OR, 1.00 [95% CI, 0.06-15.9], P=0.9), or death (OR, 1.50 [95% CI, 0.53-4.22], P=0.4) were observed between the contrast and noncontrast groups. All patients with post-CT stage 3 AKI diagnosed also had contrast-independent potential causes of AKI. LIMITATIONS: The study's small sample size and low rates of postcontrast AKI, dialysis therapy, and death limited the ability to detect an effect of contrast administration on these outcomes. Unmeasured residual confounders may limit the validity of our results. Few patients had decreased kidney function at the time of CT. CONCLUSIONS: Rates of postcontrast AKI, dialysis therapy, and death following contrast-enhanced CT were very low in this pediatric cohort. Although not detectably different, an effect of contrast on these outcomes could not be ruled out.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. McDonald JS, McDonald RJ, Tran CL, et al. Postcontrast Acute Kidney Injury in Pediatric Patients: A Cohort Study. Am J Kidney Dis. 2018. PMID: 30041876. doi:10.1053/j.ajkd.2018.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。